The US Food and Drug Administration granted clearances for PCR-based infectious disease tests from multiple entities as well as other in vitro diagnostic tests.

The new ruling reverses a jury verdict from four years ago that handed ArcherDx, which no longer exists, $4.7 million in damages.

TBI is a potential new application area for the 8-year-old company, while it continues to commercialize its stroke triage test.